The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.
 
Claire Roddie
Honoraria - Autolus Therapeutics
Consulting or Advisory Role - Autolus Therapeutics
Research Funding - Autolus Therapeutics (Inst)
Travel, Accommodations, Expenses - Autolus Therapeutics
 
Karamjeet Singh Sandhu
No Relationships to Disclose
 
Eleni Tholouli
No Relationships to Disclose
 
Paul Shaughnessy
No Relationships to Disclose
 
Pere Barba
No Relationships to Disclose
 
Manuel Nuno Guerreiro
No Relationships to Disclose
 
Deborah Yallop
No Relationships to Disclose
 
Mehrdad Abedi
No Relationships to Disclose
 
Sridhar Chaganti
No Relationships to Disclose
 
Armin Ghobadi
No Relationships to Disclose
 
Jean Yared
Consulting or Advisory Role - Kadmon; Omeros
 
Aaron Logan
No Relationships to Disclose
 
Michael Russell Bishop
Honoraria - Bristol-Myers Squibb/Celgene/Juno; Incyte; Incyte; Sanofi/Aventis
Consulting or Advisory Role - Arcellx; Autolus; BMS; crispr therapeutics; Iovance Biotherapeutics; Kite, a Gilead company; Novartis; Sana Biotechnology
Speakers' Bureau - Agios; Bristol-Myers Squibb; Incyte; Kite, a Gilead company; Sanofi
Research Funding - Arcellx (Inst); crispr therapeutics (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Expert Testimony - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - BMS; Kite/Gilead; Novartis
 
Michael Zhang
Employment - Autolus Therapeutics
Stock and Other Ownership Interests - Autolus Therapeutics
 
Wolfram Brugger
Employment - Autolus Therapeutics
Stock and Other Ownership Interests - Autolus Therapeutics
 
Martin Pule
Employment - Autolus Therapeutics
Stock and Other Ownership Interests - Autolus Therapeutics
Research Funding - Autolus Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Autolus Therapeutics
 
Jae H. Park
No Relationships to Disclose
 
Daniel J. DeAngelo
Consulting or Advisory Role - Amgen; Blueprint Medicines; Gilead Sciences; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Pfizer; takeda
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); glycomimetics (Inst); Novartis (Inst)
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Pfizer; Takeda